Recent Progress in the Treatment of AAV and its Impact on the Outcome of the Patients

Recent Progress in the Treatment of AAV and its Impact on the Outcome of the Patients 

ReachMD Healthcare Image
RestartResume

What have been the most significant changes in the treatment of patients with AAV? Discover more in this episode.

  • Overview

    Host Dr. Vladimir Tesar (General University Hospital, Prague) and Dr. David Jayne (Addenbrooke's Hospital, United Kingdom) discuss the roles of various agents in the induction and maintenance treatment of ANCA- associated vasculitis. They will explore the use of rituximab and complement inhibition in treating ANCA-associated vasculitis. This episode will address the gaps in knowledge and ongoing research in the field of ANCA-associated vasculitis.

    This episode is part of the KDIGO Conversations in Nephrology podcast series.

  • Commercial Support

    This episode is supported by Amgen.

  • Provider(s)/Educational Partner(s)

    This episode is jointly provided by KDIGO and Medtelligence

    ReachMD Healthcare Image

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free